Wedbush Reiterates Outperform on Janux Therapeutics, Maintains $74 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $74 price target.
August 08, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $74 price target.
The reiteration of an Outperform rating and a maintained price target of $74 by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100